“Mallinckrodt Plc.is based in Dublin, Ireland”. Moreover, Endurant Capital Management Lp has 4.59% invested in the company for 231,229 shares. The ratio is positive, as 73 funds sold all Mallinckrodt PLC shares owned while 148 reduced positions. Envestnet Asset Management Inc. boosted its stake in Mallinckrodt PLC by 120.6% in the first quarter. They were forecasting US$2.18 per share three months ago. AHL Partners LLP now owns 29,329 shares of the company’s stock worth $2,189,000 after buying an additional 25,906 shares in the last quarter. TheStreet raised shares of Mallinckrodt PLC from a hold rating to a buy rating in a research note on Friday, June 17th.
Advertisement
Several other analysts also recently issued reports on the stock. The majority of analysts covering the equity have either a Buy or Strong Buy recommendation on the stock, yielding a consensus score of 1.80. They now have $88.80 price objective on the stock.
08/02/2016 – Mallinckrodt plc had its “buy” rating reiterated by analysts at Guggenheim. Mallinckrodt plc got Initiated on 12-Aug-16 where investment firm Stifel Initiated the stock to Buy.
Mallinckrodt Public Limited Company (NYSE:MNK) was up +1.94% ($1.58) to $83.06 and showed a volume of 1.44 mln shares. 1443848 shares were traded on Mallinckrodt plc’s last session.
Mallinckrodt PLC NYSE:MNK has a 50 day moving average of 68.71 United States dollars and a 200 day moving average of 66.83 USD. The Market Capitalization of the company stands at 9.02 Billion. Mallinckrodt PLC has a one year low of $50.90 and a one year high of $90.64. They expect $2.25 earnings per share, up 22.28% or $0.41 from last year’s $1.84 per share. The company had revenue of $970.60 million for the quarter, compared to analysts expectations of $921.82 million.
02/19/2016 – Wells Fargo began new coverage on Mallinckrodt plc giving the company a “outperform” rating. On average, equities research analysts predict that Mallinckrodt PLC will post $8.62 EPS for the current fiscal year.
Mallinckrodt PLC said Wednesday that it will sell its nuclear imaging business for $690 million to IBA Molecular, which makes radiopharmaceutical products.
The Hazelwood-based drug manufacturer said it is moving away from nuclear imaging to continue its focus on high-growth specialty pharmaceuticals.
Advertisement
The unit includes a portfolio of diagnostic imaging products including the medical isotope molybdenum-99, the source of technetium-99m, used in ~80% of nuclear medicine procedures worldwide.
